<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The effect of <z:chebi fb="0" ids="2376">acarbose</z:chebi>, an alpha-glucosidase inhibitor, on postprandial <z:chebi fb="105" ids="17234">glucose</z:chebi> and <z:chebi fb="23" ids="18059">lipid</z:chebi> metabolism was investigated in patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Twenty patients (10 men and 10 women) with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> were studied </plain></SENT>
<SENT sid="2" pm="."><plain>A test meal was taken with or without 100 mg of <z:chebi fb="0" ids="2376">acarbose</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>The levels of plasma <z:chebi fb="105" ids="17234">glucose</z:chebi>, and serum immunoreactive insulin, <z:chebi fb="23" ids="18059">lipids</z:chebi>, <z:chebi fb="0" ids="39015">apolipoproteins</z:chebi>, and remnant-like particle cholesterol were investigated </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="2376">Acarbose</z:chebi> inhibited the postprandial increase of both plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> and serum immunoreactive insulin </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="2376">Acarbose</z:chebi> also significantly suppressed the increase of serum <z:chebi fb="4" ids="17855">triglycerides</z:chebi> at 60, 90, and 120 min (P &lt; 0.05 to P &lt; 0.01), and the increase of serum remnant-like particle cholesterol at 60 and 120 min (P &lt; 0.05) </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="2376">Acarbose</z:chebi> inhibited the postprandial decline of <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> C-II, and decreased the postprandial serum <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> C-III level </plain></SENT>
<SENT sid="7" pm="."><plain>These results suggest that <z:chebi fb="0" ids="2376">acarbose</z:chebi> may improve postprandial <z:hpo ids='HP_0003077'>hyperlipidemia</z:hpo> as well as <z:hpo ids='HP_0011998'>postprandial hyperglycemia</z:hpo> in patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
</text></document>